NCT05132049View on ClinicalTrials.gov

Pharmacokinetics and Safety Profiles After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 18, 2021

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions

Healthy

Interventions

DRUG

DA-5211

single dose administration (DA-5211 one tablet once a day)

DRUG

DA-5211-R1 + DA-5211-R2

single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)

Trial Locations (1)

07590

Bumin Hospital, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT05132049 - Pharmacokinetics and Safety Profiles After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter